CSR Activities Report 2019 CSR Activities Report 2019
Total Page:16
File Type:pdf, Size:1020Kb
CSR Activities Report 2019 CSR Activities Report 2019 Contents Editorial Policies 1 Fair Operating Practices Message from the Management 2 Promotion of Fair Operating Practices 81 Mitsubishi Tanabe Pharma’s CSR 3 Appropriate Relationships with Medical Institutions and Patient Organizations 83 Organizational Governance Prevention of Bribery and Corruption 85 Corporate Governance 7 Protection of Intellectual Property Rights 86 Code of Conduct 8 Promotion of CSR Procurement 87 Risk Management 9 VOICE 89 Compliance 11 VOICE 15 Consumer Issues Research & Development 90 Human Rights Manufacturing and Supply Chain 92 Human Rights Approach and Initiatives 16 Information Provision 98 Human Rights Issues in the Value Chain 19 Drug Safety / Quality Assurance 102 VOICE 22 Solving Issues Related to Improving Access to Healthcare 105 Labor Practices VOICE 108 Human Resources Development 23 Community Involvement and Development Promoting Diversity 26 Corporate Citizenship Policy 109 Occupational Health and Safety 34 Contributions to Medical Care and Welfare 111 VOICE 40 Development of Science and Technology 120 Environment Contributions to the Environment 121 Promotion of Local Communities 123 Environmental Management 41 Activities Addressing Social Needs 126 Medium-Term Environmental Action Plan 50 Overview of Environmental Impact / VOICE 130 Third-Party Assurance 53 Calculation Standards for Environmental Other Related Information Performance Indicators 55 External Evaluations 131 Initiatives in Energy Conservation and Data 134 Global Warming Mitigation 59 GRI Standard Comparative Table 149 Reduction of Waste, Effective Use of Water Resources 67 Explanation of Terms 158 Initiatives to Prevent Pollution and Independent Third-Party Assurance Report 161 Reduce Environmental Burdens 72 Initiatives for the Preservation of Biodiversity 75 Promotion of Environmental Communication 78 VOICE 80 This PDF was edited as CSR Activities Report 2019 and includes the content disclosed on our CSR website as of September 30, 2019. HOME>CSR>Editorial Policies Editorial Policies This website is intended to provide the Group's stakeholders, including patients, medical professionals, shareholders, investors, local communities, and employees, with information about the CSR activities implemented by the Group in fiscal 2018. Specific initiatives implemented in accordance with the Company's philosophy are presented in line with the ISO 26000 Core Subjects. The CSR Activities Report 2019 PDF version, which contains the same content as disclosed on this website, can be downloaded from the CSR Activities Report archive page. In addition, the environmental and social performance indicators listed in the CSR Activities Report 2019 PDF Version received independent third-party assurance from KPMG AZSA Sustainability Co., Ltd. Indicators that received assurance have this mark Explanations of medical and pharmaceutical terms appearing in this report have been provided to foster a wider understanding of the report's content. Applied Guidelines ISO26000; Global Reporting Initiative (GRI) Sustainability Reporting Standard; Environmental Reporting Guidelines, 2018 version, published by the Ministry of the Environment of Japan Period covered April 1, 2018, to March 31, 2019 (The report includes examples of activities from April 2019 and thereafter.) Issue timing September 2019 (Previous report: September 2018; next report: September 2020) Scope of reporting Mitsubishi Tanabe Pharma and consolidated subsidiaries in Japan and overseas. (The scope of reporting could differ in accordance with the examples being reported.) Contact information Contact Us 1 HOME>CSR>Message from the Management Message from the Management The Mitsubishi Tanabe Pharma Group's philosophy states that "We contribute to the healthier lives of people around the world through the creation of pharmaceuticals." We believe that our duty to society is to open up the future for patients and for medicine by discovering innovative pharmaceuticals and creating original value. In fiscal 2018, the Group identified seven material issues (important issues) that it must address to further define these ideas and strengthen its efforts. In identifying these material issues, we have organized their relationship with the achievement of the 17 goals set forth in the Sustainable Development Goals (SDGs), in addition to the Code of Conduct established by the Group. We will further contribute to extending people's healthy life expectancy and to realizing a sustainable society by establishing monitoring indicators for these and pursuing our business activities while evaluating and improving them. In order that each and every employee in every country in our global system has a high level of ethical standards and acts with fairness and integrity, the Group is seeking to create a global governance system. The Group will continue to improve global governance by setting up local control functions in each region, including the US, Europe, ASEAN, and China. We will also work with Mitsubishi Chemical Holdings Corporation, which has more than 700 affiliated companies worldwide, to strengthen governance and compliance in each country. Having established "Employee health, diversity and inclusion" as an important issue, we have also focused on establishing a workplace environment where diverse employees can play an active role, such as in health management, childcare and nursing care support, diverse working styles, and LGBT initiatives. These activities have been highly evaluated by external organizations. We have been certified under such programs as the Ministry of Economy, Trade and Industry's "Outstanding Enterprise in Health and Productivity Management — White 500," which recognizes companies that are implementing especially strong health and productivity management; "the Eruboshi (highest ranking)," which is based on the Act on Promotion of Women's Participation and Advancement in the Workplace; and "Platinum Kurumin," which is based on the Next Generation Nurturing Support Measures Promotion Law. We received the Special Encouragement Award at the "Ikumen Enterprise Award 2018, in the Work-Life Balance Support Category." The award is a commendation established by the Ministry of Health, Labour and Welfare to actively encourage male employees to balance parenting and career and recognize companies that seek to improve their business. Through these initiatives, the Mitsubishi Tanabe Pharma Group fulfills its corporate social responsibilities and aims to be a global research-driven pharmaceutical Group that is trusted by society. Mitsubishi Tanabe Pharma President & Representative Director 2 HOME>CSR>Mitsubishi Tanabe Pharma's CSR Mitsubishi Tanabe Pharma's CSR The Mitsubishi Tanabe Pharma Group's corporate philosophy — We contribute to the healthier lives of people around the world through the creation of pharmaceuticals — reflects universal values, and the realization of that philosophy is our social mission. The topic of corporate social responsibility is a focus of attention, and in this setting the Company needs to maintain an appropriate understanding of the changing state of affairs in society and to actively contribute to the resolution of social issues. In addition, there is a growing commitment around the world to working toward the resolution of environmental and social issues through worldwide initiatives, such as the SDGs adopted at a United Nations summit held in 2015. In this setting, companies are being called on to do more. Believing that it can continue to benefit society by responding to social demands, such as by incorporating ethical and environmental considerations in its corporate management, and not merely generating profits through business, the Group has identified the highest priority management issue as a materiality (important issues) that it needs to address. Moreover, as people engaged in the activities of a pharmaceutical company, all of our officers and employees must have a strong sense of mission and a high level of ethical standards and conduct our business activities with fairness and integrity. Through its CSR activities, the Group will contribute to extending the healthy life expectancy of people and achieving a sustainable society. ⇒Materiality https://www.mt-pharma.co.jp/shared/show.php?url=../e/company/materiality.html KAITEKI Mitsubishi Tanabe Pharma is a member of the Mitsubishi Chemical Holdings Corporation (MCHC) Group, which is working to realize KAITEKI by providing solutions to environmental and social issues and contributing to the sustainable development of society and the planet. KAITEKI means "the sustainable well-being of people, society and our planet Earth." The MCHC Group defines "KAITEKI management" as the integrated implementation of three types of management (1) management which focuses on capital efficiency, (2) management which strives to create innovation for society, and (3) management aiming to improve sustainability while maintaining a focus on time and opportunity. The MCHC Group calls the value created from the three kinds of management "KAITEKI value." All of the MCHC Group's activities target enhancement of KAITEKI value. We believe that enhancing KAITEKI Value will lead to the realization of KAITEKI. We promote this management approach aiming to generate revenue and develop ourselves sustainably while contributing to solving environmental and social issues as a company. ⇒For further information about KAITEKI, please see the MCHC website. https://www.mitsubishichem-hd.co.jp/english/kaiteki_management/kaiteki/